Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease

Biochimie

Volumn 81, Issue 5, 1999, Pages 415-424

  Di Cerbo, Alfredo ^a   Corda, Daniela ^b  

^a Unit of Endocrinology   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Arachidonic acid; Graves' disease; Phospholipase A2; Thyroid autoimmunity; TSH receptor

Indexed keywords

ADENYLATE CYCLASE; EPITOPE; IMMUNOGLOBULIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; THYROTROPIN; THYROTROPIN RECEPTOR;

ARTICLE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; PATHOGENESIS; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 0032752930     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(99)80090-X     Document Type: Article

References (118)

1. Adams D.D., Purves H.D. Abnormal responses in the assay of thyrotrophin. Proc. Univ. Otago Med. Sch. 34:1956;11-12.
2. Kriss J.P., Pleshakov V., Chien J.R. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxoedema. J. Clin. Endocrinol. Metab. 24:1964;1005-1028.
3. Rees Smith B., Hall R. Thyroid stimulating immunoglobulins in Graves' disease. Lancet. 2:1974;427-431.
4. Borges M., Ingbar J.C., Endo K., Amir S., Uchimura H., Nagataki S., Ingbar S.H. A new method for assessing the thyrotropin binding inhibitory activity in the immunoglobulins and whole serum of patients with Graves' disease. J. Clin. Endocrinol. Metab. 54:1982;552-558.
5. Southgate K., Creagh F., Teece M., Kingswood C., Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin. Endocrinol. 20:1984;539-548.
6. Hensen J., Kotulla P., Finke R., Bogner U., Badenhoop K., Meinhold H., Schleusener H. Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotropin binding-inhibiting antibodies. J. Clin. Endocrinol. Metab. 58:1984;980-987.
7. Nagayama Y., Kaufman K.D., Seto P., Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem. Biophys. Res. Commun. 165:1989;1184-1190.
8. Libert F., Lefort A., Gerard C., Parmentier M., Perret J., Ludgate M., Dumont J.E., Vassart G. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem. Biophys. Res. Commun. 165:1989;1250-1255.
9. Misrahi M., Loosfelt H., Atger M., Sar S., Guiochon-Mantel A., Milgrom E. Cloning, sequencing and expression of human TSH receptor. Biochem. Biophys. Res. Commun. 166:1990;394-403.
10. Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L., Cone R.D. Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation by tissue specific splicing. Mol. Endocrinol. 4:1990;1264-1276.
11. Akamizu T., Ikuyama S., Saji M., Kosugi S., Kozak C., McBride O.W., Kohn L.D. Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. Proc. Natl. Acad. Sci. USA. 87:1990;5677-5681.
12. Dumont J.E., Lamy F., Roger P., Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol. Rev. 72:1992;667-697.
13. Furmaniak J., Hashim F.A., Buckland P.R., Petersen V.B., Beever K., Howells R.D., Rees Smith B. Photoaffinity labelling of the TSH receptor on FRTL5 cells. FEBS Lett. 215:1987;316-322.
14. Rees Smith B., McLachlan S.M., Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocrinol. Rev. 9:1988;106-121.
15. Gennick S.E., Thomas C.G.J.R., Nayfeh S.N. Characterization of the subunit structure of the thyrotropin receptor in the FRTL-5 rat thyroid cell line. Endocrinology. 121:1987;2119-2130.
16. Nagayama Y., Rapoport B. The thyrotropin receptor 25 years after its discovery: new insight after its molecular cloning. Mol. Endocrinol. 6:1992;145-156.
17. Vassart G., Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrinol. Rev. 13:1992;596-611.
18. Parmentier M., Libert F., Maenhaut C., Lefort A., Gerard C., Perret J., VanSande J., Dumont J.E., Vassart G. Molecular cloning of the thyrotropin receptor. Science. 246:1989;1620-1622.
19. Vassart G., Parmentier M., Libert F., Dumont J.E. Molecular genetics of thyrotropin receptor. Trends Endocrinol. Metab. 2:1991;151-156.
20. Rousseau-Merck M.F., Misrahi M., Loosfelt H., Atger M., Milgrom E., Berger R. Assignment of the human thyroid stimulating hormone receptor (TSHR) gene to chromosome 14q31. Genomics. 8:1990;233-236.
21. Gross B., Misrahi M., Sar S., Milgrom E. Composite structure of the human thyrotropin receptor gene. Biochem. Biophys. Res. Commun. 177:1991;679-687.
22. Misrahi M., Milgrom E. Cleavage and shedding of the TSH receptor. Eur. J. Endocrinol. 137:1997;599-602.
23. Loosfelt H., Pichon C., Jolivet A., Misrahi M., Caillou B., Jamous M., Vannier B., Milgrom E. Two-subunit structure of the human thyrotropin receptor. Proc. Natl. Acad. Sci. USA. 89:1992;3765-3769.
24. Grossman R.F., Ban T., Duh Q.Y., Tezelman S., Jossart G., Soh E.Y., Clark O.H., Siperstein A.E. Immunoprecipitation isolates multiple TSH receptor forms from human thyroid tissue. Thyroid. 5:1995;101-105.
25. Russo D., Chazenbalk G.D., Nagayama Y., Wadsworth H.L., Seto P., Rapoport B. A new structural model for the thyrotropin (TSH) receptor, as determined by covalent cross-linking of TSH to the recombinant receptor in intact cells: evidence for a single polypeptide chain. Mol. Endocrinol. 5:1991;1607-1612.
26. Ban T., Kosugi S., Kohn L.D. Specific antibody to the thyrotropin receptor identifies multiple receptor forms in membranes of cells transfected with wild-type receptor complementary deoxyribonucleic acid: characterization of their relevance to receptor synthesis, processing, structure, and function. Endocrinology. 131:1992;815-829.
27. Misrahi M., Ghinea N., Sar S., Saunier B., Jolivet A., Loosfelt H., Cerutti M., Devauchelle G., Milgrom E. Processing of the precursors of the human thyroid-stimulating hormone receptor in various eukaryotic cells (human thyrocytes, transfected L cells and baculovirus-infected insect cells). Eur. J. Biochem. 222:1994;711-719.
28. Chazenbalk G.D., McLachlan S.M., Nagayama Y., Rapoport B. Is receptor cleavage into two subunits necessary for thyrotropin action? Biochem. Biophys. Res. Commun. 225:1996;479-484.
29. Couet J., Sar S., Jolivet A., Vu Hai M.T., Milgrom E., Misrahi M. Shedding of human thyrotropin receptor ectodomain. J. Biol. Chem. 271:1996;4545-4552.
30. Chazenbalk G.D., Tanaka K., Nagayama Y., Kakinuma A., Jaume J.C., McLachlan S.M., Rapoport B. Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites. Endocrinology. 138:1997;2893-2899.
31. Nagayama Y., Wadsworth H.L., Russo D., Chazenbalk G.D., Rapoport B. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. J. Clin. Invest. 88:1991;336-340.
32. Kohn L.D., Ban T., Okajima F., Shimura H., Shimura Y., Hidaka A., Giuliani C., Napolitano G., Kosugi S., Ikuyama S., Akamizu T., Takara K., Saji M. Cloning and regulation of glycoprotein hormone receptor genes. Weintraub B.D. Molecular Endocrinology: Basic concepts and clinical correlations. 1995;133 Raven Press, New York.
33. Kosugi S., Ban T., Akamizu T., Kohn L.D. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid stimulating antibodies and with thyroid stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors. Mol. Endocrinol. 6:1992;168-180.
34. Kosugi S., Ban T., Kohn L.D. Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor. Mol. Endocrinol. 7:1993;114-130.
35. Pastan I., Macchia V. Mechanism of thyroid-stimulating hormone action. Studies with dibutyl 3'-5'-adenosine monophosphate and lecithinase C. J. Biol. Chem. 242:1967;5757-5761.
36. Kohn L.D., Aloj S.M., Tombaccini D., Rotella C.M., Toccafondi R., Marcocci C., Corda D., Grollman E.F. The thyrotropin receptor. Litwack G. Biochemical Action of Hormones. Vol XII:1985;457 Academic Press, New York.
37. Field J.B., Ealey P.A., Marshall N.J., Cockcroft S. Thyroid-stimulating hormone stimulates increases in inositol phosphates as well as cyclic AMP in the FRTL-5 rat thyroid cell line. Biochem. J. 247:1987;519-524.
38. Dumont J.E., Jauniaux J.C., Roger P.P. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem. Sci. 14:1989;67-71.
39. 2+ and iodide efflux induced by thyrotropin and by the stimulation of α1-adrenergic receptors in cultured rat thyroid cells. J. Biol. Chem. 260:1985;9230-9236.
40. Laurent E., Mockel J., Van Sande J., Graff I., Dumont J.E. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol. Cell. Endocrinol. 52:1987;273-278.
41. Ginsberg J. Protein kinase C as a mediator of TSH and thyroid autoantibody action. Autoimmunity. 13:1992;51-59.
42. Corda D., Bizzarri C., DiGirolamo M., Valitutti S., Luini A. G protein-linked receptors in the thyroid. Ekholm R, Kohn L.D. Control of the thyroid gland. 1989;269 Plenum Press, New York.
43. Laugwitz K.L., Allgeier A., Offermanns S., Spicher K., Van Sande J., Dumont J.E., Schultz G. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc. Natl. Acad. Sci. USA. 93:1996;116-120.
44. Chazenbalk G.D., Nagayama Y., Russo D., Wadsworth H.L., Rapoport B. Functional analysis of the cytoplasmic domains of the human thyrotropin receptor by site-directed mutagenesis. J. Biol. Chem. 265:1990;20970-20975.
45. Chazenbalk G.D., Nagayama Y., Wadsworth H., Russo D., Rapoport B. Signal transduction by the human thyrotropin receptor: studies on the role of individual amino acid residues in the carboxyl terminal region of the third cytoplasmic loop. Mol. Endocrinol. 5:1991;1523-1526.
46. Kosugi S., Mori T. The first cytoplasmic loop of the thyrotropin receptor is important for phosphoinositide signaling but not for agonist-induced adenylate cyclase activation. FEBS Lett. 341:1994;162-166.
47. Kosugi S., Kohn L.D., Akamizu T., Mori T. The middle portion in the second cytoplasmic loop of the thyrotropin receptor plays a crucial role in adenylate cyclase activation. Mol. Endocrinol. 8:1994;498-509.
48. Kosugi S., Okajima F., Ban T., Hidaka A., Shenker A., Kohn L.D. Mutation of alanine 623 in the third cytoplasmic loop of the rat thyrotropin (TSH) receptor results in a loss in the phosphoinositide but not cAMP signal induced by TSH and receptor autoantibodies. J. Biol. Chem. 267:1992;24153-24156.
49. Kosugi S., Mori T. The intracellular region adjacent to plasma membrane (residues 684-692) of the thyrotropin receptor is important for phosphoinositide signaling but not for agonist-induced adenylate cyclase activation. Biochem. Biophys. Res. Commun. 199:1994;1497-1503.
50. Creagh F., Teece M., Williams S., Didcote S., Perkins W., Hashim F., Rees Smith B. An analysis of thyrotrophin receptor binding and thyroid stimulating activities in a series of Graves' sera. Clin. Endocrinol. 23:1985;395-404.
51. Vitti P., Rotella C.M., Valente W.A., Cohen J., Aloj S.M., Laccetti P., Ambesi-Impiombato F.S., Grollman E.F., Pinchera A., Toccafondi R., Kohn L.D. Characterization of the optimal stimulatory effects of Graves' monoclonal and serum immunoglobulin G on adenosine 3',5'-monophosphate production in FRTL-5 thyroid cells: a potential clinical assay. J. Clin. Endocrinol. Metab. 57:1983;782-791.
52. Rapoport B., Greenspan F.S., Filetti S., Pepitone M. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J. Clin. Endocrinol. Metab. 58:1984;332-338.
53. Zakarija M., McKenzie J.M. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinol. Metab. Clin. North Am. 16:1987;343-363.
54. McKenzie J.M., Zakarija M. Clinical Review 3. The Clinical use of thyrotropin receptor antibody measurements. J. Clin. Endocrinol. Metab. 69:1989;1093-1096.
55. Gupta M.K. Thyrotropin receptor antibodies: advances and importance of detection techniques in thyroid diseases. Clin. Biochem. 25:1992;193-199.
56. Sugenoya A., Kidd A., Row V.V., Volpe R. Correlation between thyrotropin displacing activity and human thyroid-stimulating activity by immunoglobulins from patients with Graves' disease and other thyroid disorders. J. Clin. Endocrinol. Metab. 48:1979;398-402.
57. Cho B.Y., Shong M.H., Yi K.H., Lee H.K., Koh C.S., Min H.K. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin. Endocrinol. 36:1992;585-590.
58. Davies T.F., Yeo P.P.B., Evered D.C., Clark F., Rees Smith B., Hall R. Value of the thyroid-stimulating antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease. Lancet. 1:1977;1181-1182.
59. Schleusener H., Schwander J., Fischer C., Holle R., Holl G., Badenhoop K., Hensen J., Finke R., Bogner U., Mayr W.R., Schernthaner G., Schatz H., Pickardt C.R., Kotulla P. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol. 120:1989;689-701.
60. Ikenoue H., Okamura K., Sato K., Kuroda T., Yoshinari M., Tokuyama T., Nakagawa M., Fujishima M. Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices. Acta Endocrinol. 125:1991;643-650.
61. McKenzie J.M. Neonatal Graves' disease. J. Clin. Endocrinol. Metab. 24:1964;660-668.
62. Ludgate M., Perret J., Parmentier M., Gerard C., Libert F., Dumont J.E., Vassart G. Use of the recombinant human thyrotropin receptor (TSH-R) expressed in mammalian cell lines to assay TSH-R autoantibodies. Mol. Cell. Endocrinol. 73:1990;R13-R18.
63. Takai O., Desai R.K., Seetharamaiah G.S., Jones C.A., Allaway G.P., Akamizu T., Kohn L.D., Prabhakar B.S. Prokaryotic expression of the thyrotropin receptor and identification of an immunogenic region of the protein using synthetic peptides. Biochem. Biophys. Res. Commun. 179:1991;319-326.
64. Vitti P., Elisei R., Tonacchera M., Chiovato L., Mancusi F., Rago T., Mammoli C., Ludgate M., Vassart G., Pinchera A. Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. J. Clin. Endocrinol. Metab. 76:1993;499-503.
65. Wadsworth H.L., Chazenbalk G.D., Nagayama Y., Russo D., Rapoport B. An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science. 249:1990;1423-1425.
66. Kosugi S., Ban T., Akamizu T., Kohn L.D. Site-directed mutagenesis of a portion of the extracellular domain of the rat thyrotropin receptor important in autoimmune thyroid disease and nonhomologous with gonadotropin receptors. J. Biol. Chem. 266:1991;19413-19418.
67. Drexhage H.A., Bottazzo G.F., Doniach D., Bitensky L., Chayen J. Evidence for thyroid-growth-stimulating immunoglobulins in some goitrous thyroid diseases. Lancet. 2:1980;287-292.
68. Valente W.A., Vitti P., Rotella C.M., Vaughan M.M., Aloj S.M., Grollman E.F., Ambesi-Impiombato F.S., Kohn L.D. Antibodies that promote thyroid growth. A distinct population of thyroid-stimulating autoantibodies. New Engl. J. M. 309:1983;1028-1034.
69. Van DerGaag R.D., Drexhage H.A., Wiersinga W.M., Brown R.S., Docter R., Bottazzo G.F., Doniach D. Further studies on thyroid growth-stimulating immunoglobulins in euthyroid nonendemic goiter. J. Clin. Endocrinol. Metab. 60:1985;972-979.
70. Miyauchi A., Amino N., Tamaki H., Kuma K. Coexistence of thyroid-stimulating and thyroid-blocking antibodies in a patient with Graves' disease who had transient hypothyroidism. Am. J. M. 85:1988;418-420.
71. Kasagi K., Takeda K., Goshi K., Takamatsu J., Hidaka A., Hatabu H., Misaki T., Iida Y., Kuma K., Konishi J. Presence of both stimulating and blocking types of TSH-receptor antibodies in sera from three patients with primary hypothyroidism. Clin. Endocrinol. 32:1990;253-260.
72. Morita T., Tamai H., Oshima A., Mukuta T., Fukata S., Kuma K., Kumagai L.F., Nagataki S. The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. J. Clin. Endocrinol. Metab. 71:1990;1051-1055.
73. Bech K., Bliddal H., Siersbaek-Nielsen K., Friis T. Production of non-stimulatory immunoglobulins that inhibit TSH binding in Graves' disease after radioiodine administration. Clin. Endocrinol. 17:1982;395-402.
74. Yoshida K., Aizawa Y., Kaise N., Fukazawa H., Kiso Y., Sayama N., Hori H., Nakazato N., Tani J., Abe K. Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease. Clin. Endocrinol. 48:1998;17-22.
75. Kung A.W.C., Jones B.M. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. J. Clin. Endocrinol. Metab. 83:1998;514-518.
76. Amino N., Watanabe Y., Tamaki H., Iwatani Y., Miyai K. In vitro conversion of blocking type anti-TSH receptor antibody to the stimulating type by anti-human IgG antibodies. Clin. Endocrinol. 27:1987;615-624.
77. Taniguchi S., Yoshida A., Shigemasa C., Mitani Y., Ueta Y., Urabe K., Mashiba H. The mechanism involved in the conversion of thyrotropin receptor-bound blocking-type immunoglobulin G (IgG) to the stimulating-type by anti-human IgG antibodies. Endocrinology. 126:1990;796-803.
78. Tamai H., Kasagi K., Takaichi Y., Takamatsu J., Komaki G., Matsubayashi S., Konishi J., Kuma K., Kumagai L.F., Nagataki S. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J. Clin. Endocrinol. Metab. 69:1989;49-53.
79. Shigemasa C., Mitani Y., Taniguchi S., Adachi T., Ueta Y., Urabe K., Miyazaki S., Tanaka T., Yoshida A., Mashiba H. Three patients who spontaneously developed persistent hypothyroidism during or following treatment with antithyroid drugs for Graves' hyperthyroidism. Arch. Intern. M. 150:1990;1105-1109.
80. Takasu N., Yamada T., Sato M., Nakagawa M., Komiya I., Nagasawa Y., Aisawa T. Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clin. Endocrinol. 33:1990;687-698.
81. Cho B.Y., Shong Y.K., Lee H.K., Koh C.S., Min H.K. Graves' hyperthyroidism following primary hypothyroidism: sequential changes in various activities of thyrotropin receptor antibodies. Acta Endocrinol. 120:1989;447-450.
82. Takeda K., Takamatsu J., Kasagi K., Sakane S., Ikegami Y., Isotani H., Majima T., Majima M., Kitaoka H., Iida Y., Ikekubo K., Konishi J., Mozai T. Development of hyperthyroidism following primary hypothyroidism: a case report with changes in thyroid-related antibodies. Clin. Endocrinol. 28:1988;341-344.
83. Kouki T., Inui T., Yamashiro K., Hachiya T., Ochi Y., Kajita Y., Takasu N., Sato Y., Nagata A. Demonstration of fragments with thyroid stimulating activity from thyroid stimulation blocking antibodies-IgG molecules by papain digestion. Clin. Endocrinol. 47:1997;693-698.
84. Jin S., Hornicek F.J., Neylan D., Zakarija M., McKenzie J.M. Evidence that adenosine 3',5'-monophosphate mediates stimulation of thyroid growth in FRTL5 cells. Endocrinology. 119:1986;802-810.
85. Marcocci C., Vitti P., Lopez G., Santini F., Mammoli C., Fenzi G.F., Pinchera A. Simultaneous assay of thyroid adenylate cyclase- and growth-stimulating antibodies using FRTL-5 cells. Evidence suggesting their identity in patients with Graves' disease. Clin. Endocrinol. 30:1989;109-119.
86. Dumont J.E., Roger P.P., Ludgate M. Assays for thyroid growth immunoglobulins and their clinical implications: methods, concepts, and misconceptions. Endocrinol. Rev. 8:1987;448-452.
87. Zakarija M., McKenzie J.M. Do thyroid growth-promoting immunoglobulins exist? J. Clin. Endocrinol. Metab. 70:1990;308-310.
88. Volpe R. Autoimmunity in the endocrine system. Monogr. Endocrinol. 20:1981;1-187.
89. Zakarija M., Jin S., McKenzie J.M. Evidence supporting the identity in Graves' disease of thyroid-stimulating antibody and thyroid growth-promoting immunoglobulin G as assayed in FRTL-5 cells. J. Clin. Invest. 81:1988;879-884.
90. Tahara K., Grollman E.F., Saji M., Kohn L.D. Regulation of prostaglandin synthesis by thyrotropin, insulin or insulin-like growth factor-I, and serum in FRTL-5 rat thyroid cells. J. Biol. Chem. 266:1991;440-448.
91. Weiss S.J., Philp N.J., Grollman E.F. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 114:1984;1090-1098.
92. 2+. Endocrinology. 114:1984;1108-1113.
93. Marcocci C., Luini A., Santisteban P., Grollman E.F. Norepinephrine and thyrotropin stimulation of iodide efflux in FRTL-5 thyroid cells involves metabolites of arachidonic acid and is associated with iodination of thyroglobulin. Endocrinology. 120:1987;1127-1133.
94. Sho K., Okajima F., Majid M.A., Kondo Y. Reciprocal modulation of thyrotropin actions by P1-purinergic agonists in FRTL-5 thyroid cells. J. Biol. Chem. 266:1991;12180-12184.
95. Rees Smith B., Creagh F.M., Hashim F.A., Howells R.D., Davies-Jones E., Kajita Y., Buckland P.R., Petersen V.B. Thyrotropin receptor antibodies. Arzneimittelforschung. 35:1985;1943-1948.
96. Dallas J.S., Desai R.K., Cunningham S.J., Morris J.C., Seetharamaiah G.S., Wagle N., Goldblum R.M., Prabhakar B.S. Thyrotropin (TSH) interacts with multiple discrete regions of the TSH receptor: polyclonal rabbit antibodies to one or more of these regions can inhibit TSH binding and function. Endocrinology. 134:1994;1437-1445.
97. Laurent E., Van Sande J., Ludgate M., Corvilain B., Rocmans P., Dumont J.E., Mockel J. Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase C in human thyroid slices. J. Clin. Invest. 87:1991;1634-1642.
98. VanSande J., Lejeune C., Ludgate M., Munro D.S., Vassart G., Dumont J.E., Mockel J. Thyroid stimulating immunoglobulins, like thyrotropin activate both the cyclic AMP and the PIP2 cascades in CHO cells expressing the TSH receptor. Mol. Cell. Endocrinol. 88:1992;R1-R5.
99. Murakami M., Mori M. Identification of immunogenic regions in human thyrotropin receptor for immunoglobulin G of patients with Graves' disease. Biochem. Biophys. Res. Commun. 171:1990;512-518.
100. Murakami M., Miyashita K., Mizuma H., Yamada M., Iriuchijima T., Takeuchi T., Mori M. Discrete characteristics of antibodies raised against thyrotropin receptor-related peptides whose sequences are not conserved in the luteinizing hormone/chorionic gonadotropin receptor. J. Clin. Endocrinol. Metab. 81:1996;1747-1752.
101. Mori T., Sugawa H., Piraphatdist T., Inoue D., Enomoto T., Imura H. A synthetic oligopeptide derived from human thyrotropin receptor sequence binds to Graves' immunoglobulin and inhibits thyroid stimulating antibody activity but lacks interactions with TSH. Biochem. Biophys. Res. Commun. 178:1991;165-172.
102. Morris J.C., Berger E.R., McCormick D.J. Structure-function studies of the human thyrotropin receptor. J. Biol. Chem. 268:1993;10900-10905.
103. Ueda Y., Sugawa H., Akamizu T., Okuda J., Ueda M., Kosugi S., Ohta C., Kihou Y., Mori T. Thyroid-stimulating antibodies in sera from patients with Graves' disease are heterogeneous in epitope recognition. Eur. J. Endocrinol. 132:1995;62-68.
104. Sugawa H., Akamizu T., Kosugi S., Ueda Y., Ohta C., Okuda J., Mori T. Presence of heterogeneous thyroid-stimulating antibodies in sera from individual Graves' patients as shown by synthesized thyrotropin receptor peptide application: evidence showing two independent epitopes and a possible recognition of two epitopic regions by one antibody molecule. Eur. J. Endocrinol. 133:1995;283-293.
105. Kohn L.D., Giuliani C., Montani V., Napolitano G., Ohmori M., Ohta M., Sagi M., Schuppert F., Sheng M.H., Suzuki K., Taniguchi S.-I., Yato K., Singer D.S. Antireceptor immunity. Rayner D.C, Cooke A.R, Champion B. Thyroid immunity. 1995;115-170 Landes Biomedical, Austin/Georgetown, Texas.
106. Kim W.B., Cho B.Y., Park H.Y., Lee H.K., Kohn L.D., Tahara K., Koh C.S. Epitopes for thyroid-stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment. J. Clin. Endocrinol. Metab. 81:1996;1758-1767.
107. Kim W.B., Chung H.K., Lee H.K., Kohn L.D., Tahara K., Cho B.Y. Changes in epitopes for thyroid-stimulating antibodies in Graves' disease sera during treatment of hyperthyroidism: therapeutic implications. J. Clin. Endocrinol. Metab. 82:1997;1953-1959.
108. Di Cerbo A., Di Girolamo M., Guardabasso V., De Filippis V., Corda D. Immunoglobulins from Graves' patients stimulate phospholipase-A2 in FRTL5 thyroid cells. J. Clin. Endocrinol. Metab. 74:1992;585-592.
109. Kosugi S., Okajima F., Ban T., Hidaka A., Shenker A., Kohn L.D. Mutation of alanine 623 in the third cytoplasmic loop of the rat thyrotropin (TSH) receptor results in a loss in the phosphoinositide but not cAMP signal induced by TSH and receptor autoantibodies. J. Biol. Chem. 267:1992;24153-24156.
110. Kosugi S., Okajima F., Ban T., Hidaka A., Shenker A., Kohn L.D. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation. Mol. Endocrinol. 7:1993;1009-1020.
111. Atwa M.A., Smallridge R.C., Burch H.B., Gist I.D., Lu R., Abo-Hashem E.M., El-Kannishi M.H., Burman K.D. Immunoglobulins from Graves' disease patients stimulate phospholipase A2 and C systems in FRTL-5 and human thyroid cells. Eur. J. Endocrinol. 135:1996;322-327.
112. Bleasdale J.E., Thakur N.R., Gremban R.S., Bundy G.L., Fitzpatrick F.A., Smith R.J., Bunting S. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther. 255:1990;756-768.
113. 3 rat pituitary cells. Endocrinology. 131:1992;1883-1888.
114. Shoda Y., Kondo Y., Kobayashi I. Graves' immunoglobulin G stimulates iodide efflux in FRTL-5 thyroid cells. J. Clin. Endocrinol. Metab. 77:1993;94-97.
115. Di Cerbo A., Di Paola R., Bonati M., Zingrillo M., DeFilippis V., Corda D. Subgroups of Graves' patients identified on the basis of the biochemical activities of their immunoglobulins. J. Clin. Endocrinol. Metab. 80:1995;2785-2790.
116. Di Paola R., Menzaghi C., De Filippis V., Corda D., Di Cerbo A. Cyclooxygenase-dependent thyroid cell proliferation induced by immunoglobulins from patients with Graves' disease. J. Clin. Endocrinol. Metab. 82:1997;670-673.
117. Kohn L.D., Suzuki K., Hoffman W.H., Tombaccini D., Marcocci C., Shimojo N., Watanabe Y., Amino N., Cho B.J., Kohno Y., Hirai A., Tahara K. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto's patient whose children had intrauterine and neonatal thyroid disease. J. Clin. Endocrinol. Metab. 82:1997;3998-4009.
118. Osuga Y., Liang S.G., Dallas J.S., Wang C., Hsueh A.J.W. Soluble ecto-domain mutant of thyrotropin (TSH) receptor incapable of binding TSH neutralizes the action of thyroid-stimulating antibodies from Graves' patients. Endocrinology. 139:1998;671-676.